AT355232B - Verfahren zur herstellung von neuen steroiden der pregnan- oder 19-norpregnanreihe - Google Patents

Verfahren zur herstellung von neuen steroiden der pregnan- oder 19-norpregnanreihe

Info

Publication number
AT355232B
AT355232B AT395173A AT395173A AT355232B AT 355232 B AT355232 B AT 355232B AT 395173 A AT395173 A AT 395173A AT 395173 A AT395173 A AT 395173A AT 355232 B AT355232 B AT 355232B
Authority
AT
Austria
Prior art keywords
norpregnan
pregnan
series
producing new
new steroids
Prior art date
Application number
AT395173A
Other languages
German (de)
English (en)
Other versions
ATA395173A (de
Original Assignee
Glaxo Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Lab Ltd filed Critical Glaxo Lab Ltd
Publication of ATA395173A publication Critical patent/ATA395173A/de
Application granted granted Critical
Publication of AT355232B publication Critical patent/AT355232B/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
AT395173A 1972-05-05 1973-05-04 Verfahren zur herstellung von neuen steroiden der pregnan- oder 19-norpregnanreihe AT355232B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2114272A GB1430942A (en) 1972-05-05 1972-05-05 21-substituted 3alpha-hydroxy pregnanes

Publications (2)

Publication Number Publication Date
ATA395173A ATA395173A (de) 1979-07-15
AT355232B true AT355232B (de) 1980-02-25

Family

ID=10157915

Family Applications (1)

Application Number Title Priority Date Filing Date
AT395173A AT355232B (de) 1972-05-05 1973-05-04 Verfahren zur herstellung von neuen steroiden der pregnan- oder 19-norpregnanreihe

Country Status (16)

Country Link
JP (1) JPS4961150A (enExample)
AT (1) AT355232B (enExample)
AU (1) AU475168B2 (enExample)
BE (1) BE799102A (enExample)
CA (1) CA1013341A (enExample)
CH (1) CH617710A5 (enExample)
DE (1) DE2322532A1 (enExample)
ES (1) ES414411A1 (enExample)
FR (1) FR2183792B1 (enExample)
GB (1) GB1430942A (enExample)
IE (1) IE37596B1 (enExample)
IL (1) IL42196A (enExample)
LU (1) LU67546A1 (enExample)
NL (1) NL7306234A (enExample)
SE (1) SE400771B (enExample)
ZA (1) ZA733035B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
DK0752860T3 (da) * 1994-02-14 2000-11-13 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
JP4915427B2 (ja) * 2009-03-30 2012-04-11 ブラザー工業株式会社 液体供給ジョイント、これを使用した液体吐出ヘッド及び記録装置
EP3572417B1 (en) 2011-10-14 2025-12-17 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
BR112015003747A2 (pt) 2012-08-21 2017-07-04 Sage Therapeutics Inc métodos de tratamento de epilepsia ou estado de mal epiléptico
SG10201802389SA (en) 2013-04-17 2018-04-27 Sage Therapeutics Inc 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
ES2998982T3 (en) 2013-04-17 2025-02-24 Sage Therapeutics Inc 19-nor neuroactive steroids for inducing sedation
PL3021852T3 (pl) 2013-07-19 2021-07-05 Sage Therapeutics, Inc. Neuroaktywne steroidy, kompozycje i ich zastosowania
HUE052308T2 (hu) 2013-08-23 2021-04-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásuk
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
ME03809B (me) 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
AR102306A1 (es) 2014-10-16 2017-02-15 Sage Therapeutics Inc Esteroides neuroactivos útiles en el tratamiento de enfermedades del snc
EP3224269B1 (en) 2014-11-27 2020-02-26 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3250210B1 (en) 2015-01-26 2020-12-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN113616661A (zh) 2016-03-08 2021-11-09 萨奇治疗股份有限公司 神经活性类固醇、其组合物及用途
EP3481844B1 (en) 2016-07-11 2024-04-17 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
ES2965214T3 (es) 2016-07-11 2024-04-11 Sage Therapeutics Inc Esteroides neuroactivos sustituidos en C17, C20 y C21 y sus procedimientos de utilización
US11643434B2 (en) 2019-05-31 2023-05-09 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1346292A (fr) * 1962-09-14 1963-12-20 Roussel Uclaf Nouveau procédé de préparation des 21-amino stéroïdes
US3144446A (en) * 1963-12-20 1964-08-11 Upjohn Co Mono and bis nu-(3alpha, 17alpha-dihydroxy-11, 20-dioxo-5beta-pregnan-21-yl) quaternary ammonium salts of triethylenediamine

Also Published As

Publication number Publication date
GB1430942A (en) 1976-04-07
IL42196A0 (en) 1973-07-30
LU67546A1 (enExample) 1973-07-13
FR2183792A1 (enExample) 1973-12-21
JPS4961150A (enExample) 1974-06-13
BE799102A (fr) 1973-11-05
ES414411A1 (es) 1976-02-01
CH617710A5 (en) 1980-06-13
CA1013341A (en) 1977-07-05
DE2322532A1 (de) 1973-11-22
IE37596L (en) 1973-11-05
NL7306234A (enExample) 1973-11-07
ATA395173A (de) 1979-07-15
SE400771B (sv) 1978-04-10
ZA733035B (en) 1974-04-24
IE37596B1 (en) 1977-08-31
FR2183792B1 (enExample) 1977-07-15
AU5528473A (en) 1974-11-07
IL42196A (en) 1978-10-31
AU475168B2 (en) 1976-08-12

Similar Documents

Publication Publication Date Title
AT355232B (de) Verfahren zur herstellung von neuen steroiden der pregnan- oder 19-norpregnanreihe
AT341684B (de) Verfahren zur herstellung des neuen tri-p-toluolsulfonats von s-adenosyl -l-methionin
AT356809B (de) Verfahren zur herstellung von neuen enolderivaten
AT329076B (de) Verfahren zur herstellung von neuen 1-aminouracilen
AT329203B (de) Verfahren zur herstellung von neuen heptapeptiden
ATA583473A (de) Verfahren zur herstellung von neuen sufonamidodiphenylathern
AT323339B (de) Verfahren zur herstellung von neuen benzomorphanen
ATA770674A (de) Verfahren zur herstellung von neuen penicillinen
AT324312B (de) Verfahren zur herstellung von neuen trifluormethylsalicylaniliden
AT303983B (de) Verfahren zur Herstellung von neuen 17-Chlorsteroiden
AT325774B (de) Verfahren zur herstellung von neuen penicillinen
AT325767B (de) Verfahren zur herstellung von neuen penicillinen
AT329177B (de) Verfahren zur herstellung von neuen penicillinen
AT326268B (de) Verfahren zur herstellung von neuen penicillinen
AT328078B (de) Verfahren zur herstellung von neuen cyanomethylthioacetylcephalosporinen
AT324333B (de) Verfahren zur herstellung von neuen substituierten 5-chromanolen
AT323750B (de) Verfahren zur herstellung von neuen nitroimidazolyl-triazolc-pyridazinen
AT324561B (de) Verfahren zur herstellung von neuen penicillinen
AT311567B (de) Verfahren zur Herstellung von neuen Steroiden
AT316747B (de) Verfahren zur Herstellung von neuen Alkyl-7-deoxy-7-mercaptoalkylthio-α-thiolincosaminiden
AT315166B (de) Verfahren zur Herstellung von neuen 2-Acyl-5-nitrothiazolen
AT322104B (de) Verfahren zur herstellung von neuen pyrono-rifamycinen
AT324298B (de) Verfahren zur herstellung von neuen substituierten bicycloalkenonen
AT314748B (de) Verfahren zur herstellung von neuen 16-methylen-9beta-10alpha-steroiden
AT312827B (de) Verfahren zur Herstellung von neuen Steroiden

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee
ELJ Ceased due to non-payment of the annual fee